Generation of stable suspension producer cell lines for serum‐free lentivirus production
Biotechnology Journal · 2024-05 · 19 (5)
DOI: 10.1002/biot.202400090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, online erschienen am 08.05.2024. Verfasst von Maximilian Klimpel und 21 weiteren Autor:innen. Beteiligte Einrichtung: CSL Innovation GmbH, Marburg, Germany. Hauptthemen laut MEDLINE: Lentivirus, Bioreactors, Genetic Vectors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL Limited.
Abstract (Originalsprache)
The production of lentiviral vectors (LVs) pseudotyped with the vesicular stomatitis virus envelope glycoprotein (VSV‐G) is limited by the associated cytotoxicity of the envelope and by the production methods used, such as transient transfection of adherent cell lines. In this study, we established stable suspension producer cell lines for scalable and serum‐free LV production derived from two stable, inducible packaging cell lines, named GPRG and GPRTG. The established polyclonal producer cell lines produce self‐inactivating (SIN) LVs carrying a WAS‐T2A‐GFP construct at an average infectious titer of up to 4.64 × 10 7 TU mL −1 in a semi‐perfusion process in a shake flask and can be generated in less than two months. The derived monoclonal cell lines are functionally stable in continuous culture and produce an average infectious titer of up to 9.38 × 10 7 TU mL −1 in a semi‐perfusion shake flask process. The producer clones are able to maintain a productivity of >1 × 10 7 TU mL −1 day −1 for up to 29 consecutive days in a non‐optimized 5 L stirred‐tank bioreactor perfusion process, representing a major milestone in the field of LV manufacturing. As the producer cell lines are based on an inducible Tet‐off expression system, the established process allows LV production in the absence of inducers such as antibiotics. The purified LVs efficiently transduce human CD34 + cells, reducing the LV quantities required for gene and cell therapy applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CSL Innovation GmbH, Marburg, Germany.
- CSL Behring AG, Bern, Switzerland.
- CSL Innovation, Melbourne, Australia.
- School of Chemical Engineering, University of Queensland, St Lucia, Australia.
- Center for Biotechnology (CeBiTec), University of Bielefeld, Bielefeld, Germany.
ORCID-Profile: Maximilian Klimpel, Tobias Brandt
Förderung
- CSL Limited
Zitieren
APA
Klimpel, M., Terrao, M., Bräuer, M., Dersch, H., Biserni, M., Melo Do Nascimento, L., Schwingal, S., Vogel, J. E., Ferlemann, C., Brandt, T., Lal, N. I., Bridgeman, K., Petzke, A., McDwyer, E., Lim, J. L., Oh, S., Brumatti, G., Garcia Minambres, A., Otte, E., …, & Laux, H. (2024). Generation of stable suspension producer cell lines for serum‐free lentivirus production. Biotechnology Journal, 19(5). https://doi.org/10.1002/biot.202400090
Vancouver
Klimpel M, Terrao M, Bräuer M, Dersch H, Biserni M, Melo Do Nascimento L, et al. Generation of stable suspension producer cell lines for serum‐free lentivirus production. Biotechnology Journal. 2024;19(5). doi:10.1002/biot.202400090
BibTeX
@article{Klimpel2024,
author = {Klimpel, Maximilian and Terrao, Monica and Bräuer, Melina and Dersch, Herbert and Biserni, Martina and Melo Do Nascimento, Larissa and Schwingal, Sarah and Vogel, Jessica E and Ferlemann, Cathrin and Brandt, Tobias and Lal, Nikki Indresh and Bridgeman, Krystal and Petzke, Alex and McDwyer, Eva and Lim, Jo Leen and Oh, Seungyoul and Brumatti, Gabriela and Garcia Minambres, Albert and Otte, Ellen and Noll, Thomas and Pirzas, Vicky and Laux, Holger},
title = {Generation of stable suspension producer cell lines for serum‐free lentivirus production},
journal = {Biotechnology Journal},
year = {2024},
volume = {19},
number = {5},
doi = {10.1002/biot.202400090}
}
EUVIMED